REG - Societe Generale SA Takeda Pharma.Co.Ltd - Form 8.3 - Takeda Pharmaceutical CO LTD

Takeda Pharmaceutical CoAnnouncement

15/08/2018 13:50

RNS Number : 9156X
Societe Generale SA
15 August 2018
 


FORM 8.3
 
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the "Code")
 
1.         KEY INFORMATION
 



(a) Full name of discloser:


Société Générale S.A.




(b) Owner or controller of interests and short positions disclosed, if different from 1(a):
     The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.


 
 
 




(c) Name of offeror/offeree in relation to whose relevant securities this form relates:
     Use a separate form for each offeror/offeree


Takeda Pharmaceutical CO LTD




(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:








(e) Date position held/dealing undertaken:
     For an opening position disclosure, state the latest practicable date prior to the disclosure


14/08/2018




(f)  In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
     If it is a cash offer or possible cash offer, state "N/A"


YES: Shire PLC
 



 
2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE
 
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
 
(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
 



Class of relevant security:
 


Ordinary




 
 


Interests


Short positions








Number


%


Number


%




(1) Relevant securities owned and/or controlled:


1,584,452


0.20


5,993,186


0.76




(2) Cash-settled derivatives:
 


4,709,797


0.60


5,026


0.00




(3) Stock-settled derivatives (including options) and agreements to purchase/sell:


121,500


0.02


0


0.00




 
     TOTAL:


6,415,749


0.82


5,998,212


0.76



           
All interests and all short positions should be disclosed.
 
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
 
(b)        Rights to subscribe for new securities (including directors' and other employee options)
 



Class of relevant security in relation to which subscription right exists:








Details, including nature of the rights concerned and relevant percentages:







 
 
3.         DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
 
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
 
The currency of all prices and other monetary amounts should be stated.
 
(a)        Purchases and sales



Class of relevant security


Purchase/sale


Number of securities


Price per unit
JPY




Ordinary


Purchase


200


4603




Ordinary


Purchase


1,000


4629




Ordinary


Purchase


100


4633




Ordinary


Purchase


100


4603




Ordinary


Purchase


300


4604




Ordinary


Purchase


1,000


4600




Ordinary


Purchase


500


4591




Ordinary


Purchase


100


4608




Ordinary


Purchase


600


4605




Ordinary


Purchase


600


4600




Ordinary


Purchase


400


4598




Ordinary


Purchase


1,000


4596




Ordinary


Purchase


1,700


4590




Ordinary


Purchase


100


4591




Ordinary


Purchase


1,000


4592




Ordinary


Purchase


1,000


4605




Ordinary


Purchase


500


4604




Ordinary


Purchase


500


4594




Ordinary


Purchase


1,000


4640




Ordinary


Purchase


400


4623.5




Ordinary


Purchase


200


4593




Ordinary


Purchase


300


4618.5




Ordinary


Purchase


200


4612




Ordinary


Purchase


400


4622




Ordinary


Purchase


200


4596




Ordinary


Purchase


100


4596




Ordinary


Purchase


100


4596




Ordinary


Purchase


300


4606




Ordinary


Purchase


100


4605




Ordinary


Purchase


400


4611




Ordinary


Purchase


100


4600.5




Ordinary


Purchase


400


4603




Ordinary


Purchase


200


4588




Ordinary


Purchase


100


4588




Ordinary


Purchase


100


4588




Ordinary


Purchase


100


4588




Ordinary


Purchase


100


4588




Ordinary


Purchase


100


4585.5




Ordinary


Purchase


300


4601




Ordinary


Purchase


100


4587.5




Ordinary


Purchase


300


4591




Ordinary


Purchase


300


4611




Ordinary


Purchase


100


4599.5




Ordinary


Purchase


300


4621




Ordinary


Purchase


200


4589.5




Ordinary


Purchase


100


4587




Ordinary


Purchase


100


4589




Ordinary


Purchase


100


4580




Ordinary


Purchase


100


4599




Ordinary


Purchase


100


4611




Ordinary


Purchase


100


4591




Ordinary


Purchase


100


4591




Ordinary


Purchase


800


4569




Ordinary


Purchase


800


4628




Ordinary


Purchase


500


4585




Ordinary


Purchase


2,100


4582




Ordinary


Purchase


700


4643




Ordinary


Purchase


200


4616




Ordinary


Purchase


100


4615




Ordinary


Purchase


700


4616




Ordinary


Purchase


2,200


4564




Ordinary


Purchase


400


4589




Ordinary


Purchase


900


4580




Ordinary


Purchase


800


4574




Ordinary


Purchase


1,200


4590




Ordinary


Purchase


1,900


4593




Ordinary


Purchase


300


4581




Ordinary


Purchase


300


4581




Ordinary


Purchase


600


4622




Ordinary


Purchase


100


4591




Ordinary


Purchase


100


4591




Ordinary


Purchase


200


4591




Ordinary


Purchase


1,500


4587




Ordinary


Purchase


84


4640




Ordinary


Purchase


80


4581




Ordinary


Sale


1,000


4567




Ordinary


Sale


200


4631




Ordinary


Sale


1,000


4640




Ordinary


Sale


200


4639




Ordinary


Sale


100


4641




Ordinary


Sale


600


4640




Ordinary


Sale


100


4627




Ordinary


Sale


600


4626




Ordinary


Sale


700


4574




Ordinary


Sale


100


4569




Ordinary


Sale


1,000


4599




Ordinary


Sale


15,500


4587




Ordinary


Sale


1,000,000


4640




Ordinary


Sale


3,500


4587




Ordinary


Sale


300


4573




Ordinary


Sale


600


4635




Ordinary


Sale


300


4597




Ordinary


Sale


300


4568.5




Ordinary


Sale


100


4592




Ordinary


Sale


200


4604




Ordinary


Sale


1,200


4635




Ordinary


Sale


500


4640




Ordinary


Sale


300


4593




Ordinary


Sale


300


4640




Ordinary


Sale


500


4594




Ordinary


Sale


1,800


4588




Ordinary


Sale


1,700


4587




Ordinary


Sale


100


4603




Ordinary


Sale


300


4603




Ordinary


Sale


1,100


4602




Ordinary


Sale


1,300


4596




Ordinary


Sale


1,000


4599




Ordinary


Sale


1,300


4600




Ordinary


Sale


400


4597




Ordinary


Sale


600


4597




Ordinary


Sale


1,000


4594




Ordinary


Sale


100


4591




Ordinary


Sale


400


4594




Ordinary


Sale


500


4590




Ordinary


Sale


500


4589




Ordinary


Sale


100


4590




Ordinary


Sale


300


4590




Ordinary


Sale


400


4591




Ordinary


Sale


400


4592




Ordinary


Sale


20,000


4587




Ordinary


Sale


16,780


4597.3766




Ordinary


Sale


84


4692








Total Purchases


34,464












Total Sales


1,079,364







 
 
 
(b)        Cash-settled derivative transactions
 



Class of relevant security


Product description
e.g. CFD


Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position


Number of reference securities


Price per unit JPY




Ordinary


CFD


Increasing a long position


16,780


4597.3766



 
 (c)       Stock-settled derivative transactions (including options)
 
(i)         Writing, selling, purchasing or varying
 



Class of relevant security


Product description e.g. call option


Writing, purchasing, selling, varying etc.


Number of securities to which option relates


Exercise price per unit


Type
e.g. American, European etc.


Expiry date


Option money paid/ received per unit JPY





































 
(ii)        Exercise
 



Class of relevant security


Product description
e.g. call option


Exercising/ exercised against


Number of securities


Exercise price per unit JPY




















 
 



 
(d)        Other dealings (including subscribing for new securities)
 



Class of relevant security


Nature of dealing
e.g. subscription, conversion


Details


Price per unit (if applicable) JPY








 
 











4.         OTHER INFORMATION
 
(a)        Indemnity and other dealing arrangements
 



Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state "none"




 
 
 



 
(b)        Agreements, arrangements or understandings relating to options or derivatives
 



Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i)  the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"




 
 
 



 
(c)        Attachments
 



Is a Supplemental Form 8 (Open Positions) attached?


YES



 
 



Date of disclosure:


15/08/2018




Contact name:


Olivier Vero




Telephone number:


+44 20 7676 6969



 
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
 
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk
 
 
 




SUPPLEMENTAL FORM 8 (OPEN POSITIONS)
 
DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.
Note 5(i) on Rule 8 of the Takeover Code (the "Code")
 
 
1.         KEY INFORMATION
 



Full name of person making disclosure:


SOCIETE GENERALE SA




Name of offeror/offeree in relation to whose relevant securities the disclosure relates:


Takeda Pharmaceutical CO LTD



 
2.         STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)
 
 



Class of relevant security


Product description e.g. call option


Written or purchased


Number of securities to which option or derivative relates


Exercise price per unit


Type


Expiry date




JPY


e.g. American, European etc.




Ordinary


OTC put-option


Sale


15,700


4707


European options


14/12/2018




Ordinary


OTC put-option


Sale


30,000


5075.10


European options


14/12/2018




Ordinary


OTC put-option


Sale


29,600


5073.65


European options


14/12/2018




Ordinary


OTC put-option


Sale


15,500


4491.40


European options


14/12/2018




Ordinary


OTC put-option


Sale


30,700


4533.90


European options


14/12/2018



 
 
 
3.         AGREEMENTS TO PURCHASE OR SELL ETC.
 



Full details should be given so that the nature of the interest or position can be fully understood:




 
 
 
 
 



 
It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.
 
The currency of all prices and other monetary amounts should be stated.
 
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
 
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RETGGUMCRUPRGPA